Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients

Ma,Nan; Li,Li‑Wei; Cheng,Jing‑Liang

doi:10.3892/ol.2014.2798

Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients

Authors:
- Nan Ma
- Li‑Wei Li
- Jing‑Liang Cheng
View Affiliations

Affiliations: Department of Interventional Radiography, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 4500052, P.R. China, Department of Anesthesia, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 4500052, P.R. China, Department of MRI, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 4500052, P.R. China
Published online on: December 12, 2014 https://doi.org/10.3892/ol.2014.2798
Pages: 651-656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A cohort study was conducted to investigate the association between vascular endothelial growth factor (VEGF) polymorphisms ‑2578C/A, ‑1154G/A and ‑634C/G and the clinical outcome of renal cell carcinoma (RCC), as well as the interaction of VEGF polymorphisms with tumor stage, metastasis and size. A total of 310 RCC patients were recruited from the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) between January 2006 and December 2007, and were followed up until December 2012. The association between the three single nucleotide polymorphisms and the overall survival of RCC patients was estimated using Cox's proportional hazard regression model. The median follow‑up duration was 34.7 months and 74 of the RCC patients succumbed due to cancer during the follow‑up period. The frequency of the VEGF ‑2578 AA genotype was significantly higher in patients classed as tumor stages III‑IV (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.24‑0.95) and larger tumors (longest diameter, >4 cm; OR, 0.44; 95% CI, 0.22‑0.89). Furthermore, the frequency of VEGF ‑634 GG was significantly higher in patients with larger tumors (longest diameter, >4 cm; OR, 0.68; 95% CI, 0.48‑0.97). The VEGF ‑2578 AA genotype was correlated with a 2.96‑fold increase in the risk of RCC‑associated mortality and was associated with a five‑year survival rate of ~25%. Therefore, the present study identified that the VEGF ‑2578C/A polymorphism may be associated with the prognosis of RCC patients, and may interact with the tumor stage and size.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
2	Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
3	Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
4	Cao Q, Wang J, Zhang M, et al: Genetic Variants in RKIP Are Associated with Clear Cell Renal Cell Carcinoma Risk in a Chinese Population. PLoS One. 9:e1092852014. View Article : Google Scholar : PubMed/NCBI
5	Mu HJ, Zou J, Xie P, Xu ZQ, Ruan J, Yang SD and Yin Y: Association of leptin receptor Lys109Arg and Gln223Arg polymorphisms with increased risk of clear cell renal cell carcinoma. Asian Pac J Cancer Prev. 15:4211–4215. 2014. View Article : Google Scholar : PubMed/NCBI
6	Patard JJ, Pouessel D, Bensalah K and Culine S: Targeted therapy in renal cell carcinoma. World J Urol. 26:135–140. 2008. View Article : Google Scholar : PubMed/NCBI
7	Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
8	Vincenti V, Cassano C, Rocchi M and Persico G: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 93:1493–1495. 1996. View Article : Google Scholar : PubMed/NCBI
9	Watson CJ, Webb NJ, Bottomley MJ and Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 12:1232–1235. 2000. View Article : Google Scholar : PubMed/NCBI
10	Koukourakis MI, Papazoglou D, Giatromanolaki A, et al: VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 46:293–298. 2004. View Article : Google Scholar : PubMed/NCBI
11	Luo T, Chen L, He P, et al: Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population. Asian Pac J Cancer Prev. 14:2433–2437. 2013. View Article : Google Scholar : PubMed/NCBI
12	Sivaprasad S, Govardhan B, Harithakrishna R, et al: Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma. Pancreatology. 13:267–272. 2013. View Article : Google Scholar : PubMed/NCBI
13	Mandal RK, Yadav SS, Panda AK and Khattri S: Vascular endothelial growth factor 936 c>T polymorphism increased oral cancer risk: evidence from a meta-analysis. Genet Test Mol Biomarkers. 17:543–547. 2013. View Article : Google Scholar : PubMed/NCBI
14	He D, Lu W, Chang K, et al: Vascular endothelial growth factor polymorphisms and risk of Alzheimer’s disease: a meta-analysis. Gene. 518:296–302. 2013. View Article : Google Scholar : PubMed/NCBI
15	Garcia-Donas J, Rodriguez-Antona C and Jonasch E: Molecular markers to predict response to therapy. Semin Oncol. 40:444–458. 2013. View Article : Google Scholar : PubMed/NCBI
16	Vrdoljak E, Rini B, Schmidinger M, et al: Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs. 24:431–440. 2013. View Article : Google Scholar : PubMed/NCBI
17	Jäkel CE, Hauser S, Rogenhofer S, et al: Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol. 2012:4732452012. View Article : Google Scholar : PubMed/NCBI
18	Kawai Y, Sakano S, Korenaga Y, Eguchi S and Naito K: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol. 52:1147–1155. 2007. View Article : Google Scholar : PubMed/NCBI
19	Sáenz-López P, Vazquez F, Cozar JM, et al: VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol. 74:98–103. 2013. View Article : Google Scholar
20	Edge SB, Byrd DR, Compton CC, et al: Kidney. AJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: pp. 2010479–2010489. 2010
21	Abe A, Sato K, Habuchi T, et al: Single nucleotide polymorphisms in the 3′ untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J Exp Med. 198:181–190. 2002. View Article : Google Scholar
22	Salven P, Teerenhovi L and Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood. 90:3167–3172. 1997.PubMed/NCBI
23	Martinez-Fierro ML, Garza-Veloz I, Rojas-Martinez A, et al: Positive association between vascular endothelial growth factor (VEGF) −2578 C/A variant and prostate cancer. Cancer Biomark. 13:235–241. 2013.
24	Chen P, Zhu J, Liu DY, et al: Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis. Med Oncol. 31:7752014. View Article : Google Scholar
25	Oh SY, Kwon HC, Kim SH, et al: The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer. 13:432013. View Article : Google Scholar : PubMed/NCBI
26	Absenger G, Szkandera J, Stotz M, et al: A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog. 52(Suppl 1): E96–E102. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hefler LA, Mustea A, Könsgen D, et al: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res. 13:898–901. 2007. View Article : Google Scholar : PubMed/NCBI
28	Shahbazi M, Fryer AA, Pravica V, et al: Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 13:260–264. 2002.
29	Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, et al: Vascular endothelial growth factor −634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep. 8:1242–1250. 2013.PubMed/NCBI
30	Supic G, Jovic N, Zeljic K, Kozomara R and Magic Z: Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients. Oral Oncol. 48:1171–1177. 2012. View Article : Google Scholar : PubMed/NCBI
31	Jin Q, Hemminki K, Enquist K, et al: Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 11:3647–3653. 2005. View Article : Google Scholar : PubMed/NCBI